HIV Infections Clinical Trial
Official title:
A Registry of Tuberculosis Cases in the CPCRA
PRIMARY: To estimate the proportion of tuberculosis patients in the CPCRA who have
drug-resistant tuberculosis (TB) and to describe the patterns of drug resistance.
SECONDARY: To compare drug resistance data on the Mycobacterium tuberculosis isolates of
HIV-infected patients to those of HIV-uninfected patients who are being followed in the
CPCRA. To assess the relationship of resistance data with geographic, demographic, and HIV
and TB risk factor information.
Geographic areas and demographic subgroups affected by the TB epidemic appear to be
congruent and associated with the concurrent HIV epidemic. The total number of CPCRA
patients who will develop, or who have experienced, confirmed TB is unknown. It is critical
to determine the depth and breadth of the current problem of drug-resistant TB.
Status | Completed |
Enrollment | 1509 |
Est. completion date | June 1994 |
Est. primary completion date | June 1994 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A and older |
Eligibility |
Patients must meet the following criteria: - CPCRA patients with confirmed pulmonary or extrapulmonary TB. Confirmed clinical TB requires a positive culture for Mycobacterium tuberculosis. NOTE: - There is no requirement that patients have HIV infection. |
Time Perspective: Cross-Sectional
Country | Name | City | State |
---|---|---|---|
United States | Bronx Lebanon Hosp Ctr | Bronx | New York |
United States | Addiction Research and Treatment Corp | Brooklyn | New York |
United States | AIDS Research Alliance - Chicago | Chicago | Illinois |
United States | Denver CPCRA / Denver Public Hlth | Denver | Colorado |
United States | Comprehensive AIDS Alliance of Detroit | Detroit | Michigan |
United States | Henry Ford Hosp | Detroit | Michigan |
United States | Louisiana Comm AIDS Rsch Prog / Tulane Univ Med | New Orleans | Louisiana |
United States | Clinical Directors Network of Region II | New York | New York |
United States | Harlem AIDS Treatment Group / Harlem Hosp Ctr | New York | New York |
United States | North Jersey Community Research Initiative | Newark | New Jersey |
United States | Portland Veterans Adm Med Ctr / Rsch & Education Grp | Portland | Oregon |
United States | Richmond AIDS Consortium | Richmond | Virginia |
United States | Veterans Administration Med Ctr / Regional AIDS Program | Washington | District of Columbia |
Lead Sponsor | Collaborator |
---|---|
National Institute of Allergy and Infectious Diseases (NIAID) |
United States,
Gordin FM, Nelson ET, Matts JP, Cohn DL, Ernst J, Benator D, Besch CL, Crane LR, Sampson JH, Bragg PS, El-Sadr W. The impact of human immunodeficiency virus infection on drug-resistant tuberculosis. Am J Respir Crit Care Med. 1996 Nov;154(5):1478-83. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |